文献速递白血病

黏连蛋白单倍不足与inv(16)协同增强Fli1转录程序促进急性髓系白血病

Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance.
PubMed 文献 · Leukemia · 2026-07-27

该研究利用inv(16)伴Smc3单倍不足的小鼠模型,意外发现Smc3缺失缩短白血病潜伏期,并在白血病前造血干祖细胞中观察到染色质可及性增加且富集Fli1结合基序,单细胞测序显示ST-HSC中Fli1表达及其靶基因增强,且Fli1对inv(16); Smc3Δ/+ AML的维持必不可少。

要点

  • 黏连蛋白单倍不足可加速inv(16)驱动的AML,与常见预期相反。
  • 白血病前HSPC中染色质可及性增加并富集Fli1结合基序。
  • Fli1是黏连蛋白突变AML的潜在治疗脆弱点。

核心结论

  • 黏连蛋白单倍不足增强inv(16)驱动AML的侵袭性,并揭示Fli1为黏连蛋白突变AML的治疗脆弱点。

研究设计与样本

  • 使用inv(16)伴Smc3单倍不足(Smc3Δ/+)的小鼠模型,对比inv(16); Smc3+/+小鼠。
  • 对白血病前造血干祖细胞(HSPC)进行染色质可及性检测和单细胞RNA测序(scRNA-seq)。

主要发现

  • inv(16); Smc3Δ/+小鼠较inv(16); Smc3+/+小鼠白血病潜伏期缩短。
  • 白血病发生前,inv(16); Smc3Δ/+ HSPC中染色质可及性增加,且富集Fli1 DNA结合基序。
  • scRNA-seq显示白血病前HSPC的ST-HSC中Fli1表达增加,Fli1靶基因表达增强。
  • Fli1对inv(16); Smc3Δ/+ AML的维持阶段必不可少。

临床怎么用

  • 在inv(16) AML中需关注黏连蛋白突变状态,其可能影响疾病侵袭性。
  • Fli1可作为黏连蛋白突变AML的潜在治疗靶点进行探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Core binding factor (CBF) acute myeloid leukemias typically harbor the translocations t(8;21) or inv(16). As cohesin mutations are less commonly observed with inv(16) than with t(8;21), we hypothesized that they may negatively impact inv(16)-driven AML. Using a mouse model of inv(16) with haploinsufficiency of the cohesin subunit Smc3, we paradoxically found that inv(16); Smc3Δ/+ mice have a reduced leukemic latency compared to inv(16); Smc3+/+ mice, disproving our initial hypothesis and instead suggesting a role for cohesin loss in enhancing inv(16)-driven disease. Consistent with the known role of cohesin haploinsufficiency in altering chromatin accessibility, we demonstrated an increase in chromatin accessibility in inv(16); Smc3Δ/+ hematopoietic stem and progenitor cells (HSPCs) prior to leukemia development, with an enrichment for Fli1 DNA binding motifs. Through scRNA-seq on pre-leukemic HSPCs, we observe an increase in Fli1 expression and enhanced Fli1 target expression in ST-HSCs. We further show that Fli1 is essential for the maintenance stage of inv(16); Smc3Δ/+ AML. Our data demonstrate a role for cohesin loss in enhancing the aggressiveness of inv(16)-driven AML and identify Fli1 as a previously unrecognized therapeutic vulnerability in cohesin-mutated AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Meyer AE, Heimbruch KE, Pulakanti K, et al. Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance. Leukemia. 2026. PMID: 42509256. doi:10.1038/s41375-026-03070-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。